Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Yao on Health-Related QOL in Patients With Neuroendocrine Tumors

James C. Yao, MD
Published: Wednesday, Sep 28, 2016



James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study exploring health-related quality of life (QOL) in patients with neuroendocrine tumors (NETs).

Researchers discussed that patients with active NETs were associated with a decreased QOL. In patients whose tumors were resected and their disease was in remission, their QOL was closer to the general population. It was also found that patients with carcinoid syndrome had QOL issues impacted by their disease.

Further analyses concluded that 2 or 3 bowel movements daily had minimal impact on patient QOL. However, those with 4 or more bowel movements daily had a decreased QOL.


James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study exploring health-related quality of life (QOL) in patients with neuroendocrine tumors (NETs).

Researchers discussed that patients with active NETs were associated with a decreased QOL. In patients whose tumors were resected and their disease was in remission, their QOL was closer to the general population. It was also found that patients with carcinoid syndrome had QOL issues impacted by their disease.

Further analyses concluded that 2 or 3 bowel movements daily had minimal impact on patient QOL. However, those with 4 or more bowel movements daily had a decreased QOL.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x